📝Today we share the #Review "Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors" 👨🔬by Qiuqiang Chen et al. Huzhou University Find out more here👉 https://lnkd.in/dHMQUY3R Keywords: CAR (chimeric antigen receptor); antigen; heterogeneity
Cancers MDPI’s Post
More Relevant Posts
-
Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI
Long-term severe hypoxia adaptation induces non-canonical EMT and a novel Wilms Tumor 1 (WT1) isoform https://lnkd.in/eSrfvnv6
-
In our latest blog, we break down our April community roundtable discussion and delve into the promising role of Bruton's tyrosine kinase (BTK) inhibitors in treating both classic HCL and HCL variants. This blog highlights current and past discussions, including patient experience and professional research. Check out the blog (and past entries) at: https://lnkd.in/gtmCJYyr
-
-
#TK2dTuesday is on September 10! Come together to learn more about TK2d (Thymidine Kinase 2 deficiency) and support those affected. Together, we can take on TK2d. #TK2dTogether #TK2dAwarenessDay #Mito #TK2d #raredisease #mitochondrialdisease
-
-
#TK2dTuesday is on September 10! Come together to learn more about TK2d (Thymidine Kinase 2 deficiency) and support those affected. Together, we can take on TK2d. #TK2dTogether #TK2dAwarenessDay #Mito #TK2d #raredisease #mitochondrialdisease
-
-
#TK2dTuesday is on September 10! Come together to learn more about TK2d (Thymidine Kinase 2 deficiency) and support those affected. Together, we can take on TK2d. #TK2dTogether #TK2dAwarenessDay #Mito #TK2d #raredisease #mitochondrialdisease
-
-
Chief Medical Officer | Driving Organizational Impact and Transformation at UCB
Join forces with us for TK2d awareness day TK2d is a rare genetic mitochondrial disease Mitochondrial diseases are a group of rare, debilitating, and often fatal conditions with a severe impact on daily living and quality of life. TK2d is a type of mitochondrial disease called mitochondrial DNA depletion and deletion syndrome (MDDS). There are many types of mitochondrial diseases, so while they are rare, it is estimated that 1 in every 5,000 people is affected.
#TK2dTuesday is on September 10! Come together to learn more about TK2d (Thymidine Kinase 2 deficiency) and support those affected. Together, we can take on TK2d. #TK2dTogether #TK2dAwarenessDay #Mito #TK2d #raredisease #mitochondrialdisease
-
-
SVP Marketing & Corporate Strategy at Axion BioSystems | PhD | Discover the Functionality of Your Cells
Multiplex your CAR T cell-mediated cytotoxicity and cytokine release assays. If you are at #AACR2024 today, visit Sierra Barnes’ poster #4017 (Section 2, Board 26) to learn more. Abstract Title: CAR T cell-mediated cytotoxicity and cytokine release in response to varying levels of antigen expression on target cells #AACR24 #CancerResearch #CellTherapy #CARTcell #AxionBio Viswanath Lanka, David Greenberg, Steven Book, Rachel Osby, Julien Bradley
-
-
Our experience of clinical iPSC lines showing differntiation into NK cells. More information including live imaging of human iNK cells engulfing K562 cells, availabe through below link!
🔬We have extensively validated our Clinical iPSC lines, generated with our StemRNA 5.0 Clinical Reprogramming Technology. As part of this process, we differentiated these iPSCs into a variety of cell types. For example, our clinical iPSC lines show efficient differentiation into Natural Killer (NK) Cells. ✍️ Find out more in our latest blog on clinical iPSC-derived NK cells (iNK cells): https://hubs.li/Q02TYW7X0 🌐 Explore our updated webpage: https://hubs.li/Q02TY_xs0 #CellularTherapy #RegenerativeMedicine #StemCells
-
-
#TK2dTuesday is on September 10! Come together to learn more about TK2d (Thymidine Kinase 2 deficiency) and support those affected. Together, we can take on TK2d. #TK2dTogether #TK2dAwarenessDay #Mito #TK2d #raredisease #mitochondrialdisease
-
-
Passionate new leader focused on making a difference through progressing science and developing people.
Utilization of a stroma-free system with EZH1 knockdown (repressor of lymphoid lineage) for improved iPSC to T cell differentiation (denoted EZ-T) *EZ-T cells display molecular signatures similar to peripheral blood TCRab T cells *EZ-T cells display effector and memory-like phenotype *CAR EZ-T cells exhibit enhanced antitumor activity and persistence #CAR #CellTherapy
